vs

Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and i3 Verticals, Inc. (IIIV). Click either name above to swap in a different company.

i3 Verticals, Inc. is the larger business by last-quarter revenue ($52.7M vs $27.6M, roughly 1.9× Beta Bionics, Inc.). i3 Verticals, Inc. runs the higher net margin — 0.9% vs -79.3%, a 80.2% gap on every dollar of revenue. On growth, Beta Bionics, Inc. posted the faster year-over-year revenue change (56.6% vs -14.6%).

Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.

The Prusa i3 is a family of fused filament fabrication 3D printers, manufactured by Czech company Prusa Research under the trademarked name Original Prusa i3. Part of the RepRap project, Prusa i3 printers were called the most used 3D printer in the world in 2016. The first Prusa i3 was designed by Josef Průša in 2012, and was released as a commercial kit product in 2015. The latest model is available in both kit and factory assembled versions. The Prusa i3's comparable low cost and ease of co...

BBNX vs IIIV — Head-to-Head

Bigger by revenue
IIIV
IIIV
1.9× larger
IIIV
$52.7M
$27.6M
BBNX
Growing faster (revenue YoY)
BBNX
BBNX
+71.2% gap
BBNX
56.6%
-14.6%
IIIV
Higher net margin
IIIV
IIIV
80.2% more per $
IIIV
0.9%
-79.3%
BBNX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BBNX
BBNX
IIIV
IIIV
Revenue
$27.6M
$52.7M
Net Profit
$-21.9M
$484.0K
Gross Margin
59.5%
Operating Margin
-47.4%
3.1%
Net Margin
-79.3%
0.9%
Revenue YoY
56.6%
-14.6%
Net Profit YoY
23.6%
-76.5%
EPS (diluted)
$-0.49
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBNX
BBNX
IIIV
IIIV
Q1 26
$27.6M
Q4 25
$32.1M
$52.7M
Q3 25
$27.3M
$46.0M
Q2 25
$23.2M
$51.9M
Q1 25
$17.6M
$63.1M
Q4 24
$52.2M
Q3 24
$32.0M
Q2 24
$46.2M
Net Profit
BBNX
BBNX
IIIV
IIIV
Q1 26
$-21.9M
Q4 25
$-13.5M
$484.0K
Q3 25
$-14.2M
$3.1M
Q2 25
$-16.9M
$12.9M
Q1 25
$-28.7M
$-154.0K
Q4 24
$2.1M
Q3 24
$117.9M
Q2 24
$-7.5M
Gross Margin
BBNX
BBNX
IIIV
IIIV
Q1 26
59.5%
Q4 25
59.0%
Q3 25
55.5%
Q2 25
53.8%
Q1 25
50.9%
Q4 24
Q3 24
Q2 24
Operating Margin
BBNX
BBNX
IIIV
IIIV
Q1 26
-47.4%
Q4 25
-50.2%
3.1%
Q3 25
-62.5%
3.2%
Q2 25
-85.5%
-9.3%
Q1 25
-105.7%
8.0%
Q4 24
3.9%
Q3 24
10.6%
Q2 24
-2.8%
Net Margin
BBNX
BBNX
IIIV
IIIV
Q1 26
-79.3%
Q4 25
-41.9%
0.9%
Q3 25
-52.1%
6.7%
Q2 25
-72.6%
24.8%
Q1 25
-162.5%
-0.2%
Q4 24
3.9%
Q3 24
368.2%
Q2 24
-16.3%
EPS (diluted)
BBNX
BBNX
IIIV
IIIV
Q1 26
$-0.49
Q4 25
$-0.16
$0.02
Q3 25
$-0.33
$0.14
Q2 25
$-0.39
$0.50
Q1 25
$-0.93
$0.00
Q4 24
$0.08
Q3 24
$4.93
Q2 24
$-0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBNX
BBNX
IIIV
IIIV
Cash + ST InvestmentsLiquidity on hand
$199.5M
$37.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$271.2M
$358.5M
Total Assets
$304.4M
$595.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBNX
BBNX
IIIV
IIIV
Q1 26
$199.5M
Q4 25
$219.1M
$37.5M
Q3 25
$228.7M
$66.7M
Q2 25
$249.7M
$55.5M
Q1 25
$231.5M
$7.7M
Q4 24
$85.6M
Q3 24
$86.5M
Q2 24
$9.7M
Total Debt
BBNX
BBNX
IIIV
IIIV
Q1 26
Q4 25
Q3 25
$0
Q2 25
$0
Q1 25
$12.0M
Q4 24
$26.2M
Q3 24
$26.2M
Q2 24
$374.1M
Stockholders' Equity
BBNX
BBNX
IIIV
IIIV
Q1 26
$271.2M
Q4 25
$287.6M
$358.5M
Q3 25
$294.8M
$389.6M
Q2 25
$301.6M
$383.3M
Q1 25
$313.8M
$385.2M
Q4 24
$375.0M
Q3 24
$379.7M
Q2 24
$249.7M
Total Assets
BBNX
BBNX
IIIV
IIIV
Q1 26
$304.4M
Q4 25
$328.7M
$595.9M
Q3 25
$330.0M
$638.4M
Q2 25
$330.0M
$623.3M
Q1 25
$338.0M
$646.4M
Q4 24
$726.2M
Q3 24
$730.7M
Q2 24
$861.7M
Debt / Equity
BBNX
BBNX
IIIV
IIIV
Q1 26
Q4 25
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.03×
Q4 24
0.07×
Q3 24
0.07×
Q2 24
1.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBNX
BBNX
IIIV
IIIV
Operating Cash FlowLast quarter
$14.1M
Free Cash FlowOCF − Capex
$13.8M
FCF MarginFCF / Revenue
26.2%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
29.18×
TTM Free Cash FlowTrailing 4 quarters
$6.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBNX
BBNX
IIIV
IIIV
Q1 26
Q4 25
$-8.6M
$14.1M
Q3 25
$-8.7M
$14.0M
Q2 25
$-13.6M
$7.4M
Q1 25
$-20.0M
$-27.1M
Q4 24
$11.5M
Q3 24
$15.1M
Q2 24
$8.1M
Free Cash Flow
BBNX
BBNX
IIIV
IIIV
Q1 26
Q4 25
$-10.5M
$13.8M
Q3 25
$-10.0M
$13.5M
Q2 25
$-15.4M
$6.8M
Q1 25
$-20.3M
$-27.6M
Q4 24
$11.0M
Q3 24
$14.6M
Q2 24
$7.2M
FCF Margin
BBNX
BBNX
IIIV
IIIV
Q1 26
Q4 25
-32.8%
26.2%
Q3 25
-36.7%
29.5%
Q2 25
-66.2%
13.1%
Q1 25
-115.1%
-43.8%
Q4 24
21.1%
Q3 24
45.6%
Q2 24
15.6%
Capex Intensity
BBNX
BBNX
IIIV
IIIV
Q1 26
Q4 25
5.9%
0.6%
Q3 25
4.7%
0.9%
Q2 25
7.7%
1.0%
Q1 25
1.9%
0.8%
Q4 24
0.9%
Q3 24
1.7%
Q2 24
1.9%
Cash Conversion
BBNX
BBNX
IIIV
IIIV
Q1 26
Q4 25
29.18×
Q3 25
4.52×
Q2 25
0.57×
Q1 25
Q4 24
5.59×
Q3 24
0.13×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BBNX
BBNX

Segment breakdown not available.

IIIV
IIIV

License And Service$35.7M68%
Proprietary Payments Revenue$14.5M27%
Other Revenue$2.5M5%

Related Comparisons